title: Effect of different sintering methods on bioactivity and release of proteins from PLGA microspheres.
abstract: Macromolecule release from poly(d,l-lactide-co-glycolide) (PLGA) microspheres has been well-characterized, and is a popular approach for delivering bioactive signals from tissue-engineered scaffolds. However, the effect of some processing solvents, sterilization, and mineral incorporation (when used in concert) on long-term release and bioactivity has seldom been addressed. Understanding these effects is of significant importance for microsphere-based scaffolds, given that these scaffolds are becoming increasingly more popular, yet growth factor activity following sintering and/or sterilization is heretofore unknown. The current study evaluated the 6-week release of transforming growth factor (TGF)-β3 and bone morphogenetic protein (BMP)-2 from PLGA and PLGA/hydroxyapatite (HAp) microspheres following exposure to ethanol (EtOH), dense phase carbon dioxide (CO2), or ethylene oxide (EtO). EtO was chosen based on its common use in scaffold sterilization, whereas EtOH and CO2 were chosen given their importance in sintering microspheres together to create scaffolds. Release supernatants were then used in an accelerated cell stimulation study with human bone marrow stromal cells (hBMSCs) with monitoring of gene expression for major chondrogenic and osteogenic markers. Results indicated that in microspheres without HAp, EtOH exposure led to the greatest amount of delivery, while those treated with CO2 delivered the least growth factor. In contrast, formulations with HAp released almost half as much protein, regardless of EtOH or CO2 exposure. Notably, EtO exposure was not found to significantly affect the amount of protein released. Cell stimulation studies demonstrated that eluted protein samples performed similarly to positive controls in PLGA-only formulations, and ambiguously in PLGA/HAp composites. In conclusion, the use of EtOH, subcritical CO2, and EtO in microsphere-based scaffolds may have only slight adverse effects, and possibly even desirable effects in some cases, on protein availability and bioactivity.
authors.affiliation: Orbis Biosciences, 2002 W. 39th Ave., Kansas City, KS 66103, USA.
authors.forename: Nathan H
authors.initials: NH
authors.lastname: Dormer
authors.forename: Vineet
authors.initials: V
authors.lastname: Gupta
authors.forename: Aaron M
authors.initials: AM
authors.lastname: Scurto
authors.forename: Cory J
authors.initials: CJ
authors.lastname: Berkland
authors.forename: Michael S
authors.initials: MS
authors.lastname: Detamore
mesh_terms: D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D020219:Chondrogenesis / Q000187:drug effects / Q000235:genetics; D017886:Durapatite / Q000737:chemistry; D005786:Gene Expression Regulation / Q000187:drug effects; D005898:Glass / Q000737:chemistry; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008863:Microspheres; D010012:Osteogenesis / Q000187:drug effects / Q000235:genetics; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D023822:Tissue Engineering / Q000379:methods*; D053782:Transforming Growth Factor beta3 / Q000494:pharmacology*; D044366:Transition Temperature
chemical_list: D055396:Bone Morphogenetic Protein 2; D053782:Transforming Growth Factor beta3; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D017886:Durapatite
keywords: CO(2); Ethanol; Growth factors; Hydroxyapatite; Microspheres; PLGA
references.citation: Injury. 2010 Jul;41(7):693-701
references.pmid: 20035935
references.citation: Adv Drug Deliv Rev. 2008 Jan 14;60(2):184-98
references.pmid: 18045729
references.citation: J Control Release. 2009 Apr 17;135(2):119-26
references.pmid: 19154763
references.citation: Ann Biomed Eng. 2010 Jun;38(6):2167-82
references.pmid: 20379780
references.citation: J Control Release. 2006 Jun 28;113(2):102-10
references.pmid: 16740332
references.citation: J Biomed Mater Res A. 2010 Sep 1;94(3):870-6
references.pmid: 20336753
references.citation: J Craniomaxillofac Surg. 2005 Apr;33(2):79-84
references.pmid: 15804584
references.citation: Biomaterials. 2000 Dec;21(23):2475-90
references.pmid: 11055295
references.citation: J Mater Sci Mater Med. 2008 Mar;19(3):1109-16
references.pmid: 17701313
references.citation: J Biomed Mater Res A. 2010 Mar 1;92(3):913-21
references.pmid: 19291683
references.citation: Acta Biomater. 2009 Jan;5(1):23-8
references.pmid: 18838348
references.citation: Tissue Eng. 2006 Mar;12(3):537-46
references.pmid: 16579687
references.citation: Pharm Res. 2000 Oct;17(10):1159-67
references.pmid: 11145219
references.citation: J Biomech Eng. 2000 Jun;122(3):289-92
references.pmid: 10923299
references.citation: Tissue Eng Part A. 2009 Sep;15(9):2595-604
references.pmid: 19195987
references.citation: J Pharm Sci. 1999 Feb;88(2):215-20
references.pmid: 9950641
references.citation: Tissue Eng Part C Methods. 2008 Dec;14(4):299-309
references.pmid: 18795865
references.citation: J Oral Maxillofac Surg. 2011 Jun;69(6):e50-7
references.pmid: 21470747
references.citation: Ann Biomed Eng. 2010 Jun;38(6):1937
references.pmid: 20437202
references.citation: Acta Biomater. 2010 Feb;6(2):455-65
references.pmid: 19616135
references.citation: J Pharm Sci. 1999 Dec;88(12):1320-5
references.pmid: 10585229
references.citation: J Control Release. 2009 Mar 4;134(2):81-90
references.pmid: 19071168
references.citation: J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S82-91
references.pmid: 11314800
references.citation: Tissue Eng Part A. 2011 Nov;17(21-22):2845-55
references.pmid: 21815822
references.citation: Pharm Res. 2007 Feb;24(2):258-64
references.pmid: 17191092
references.citation: Nat Biotechnol. 2000 Jan;18(1):24-5
references.pmid: 10625383
references.citation: J Control Release. 2000 Sep 3;68(3):361-72
references.pmid: 10974390
references.citation: Acta Biomater. 2009 Feb;5(2):661-9
references.pmid: 18990616
references.citation: Eur J Pharm Biopharm. 2005 Apr;59(3):375-88
references.pmid: 15760718
references.citation: Int J Pharm. 2008 Feb 28;350(1-2):14-26
references.pmid: 18162341
references.citation: J Biomed Mater Res A. 2011 Mar 1;96(3):595-607
references.pmid: 21254391
references.citation: Int J Pharm. 2010 Jul 15;394(1-2):99-105
references.pmid: 20472046
references.citation: Pharm Res. 2000 Jan;17(1):100-6
references.pmid: 10714616
references.citation: Acta Biomater. 2010 Apr;6(4):1569-74
references.pmid: 19896564
references.citation: Adv Drug Deliv Rev. 2007 May 30;59(4-5):339-59
references.pmid: 17499384
references.citation: J Control Release. 2009 Feb 20;134(1):26-34
references.pmid: 19027807
references.citation: Tissue Eng Part B Rev. 2008 Dec;14(4):341-66
references.pmid: 18803499
references.citation: Pharm Dev Technol. 2005;10(2):299-307
references.pmid: 15926679
references.citation: Pharm Res. 2008 Dec;25(12):2896-909
references.pmid: 18709447
references.citation: Acta Biomater. 2010 Jan;6(1):137-43
references.pmid: 19660579
references.citation: J Biomed Mater Res. 2000 Jun 5;50(3):452-62
references.pmid: 10737888
references.citation: Biomaterials. 1996 Jan;17(2):93-102
references.pmid: 8624401
references.citation: Biotechnol Bioeng. 2008 Jan 1;99(1):223-34
references.pmid: 17570710
references.citation: J Control Release. 2001 May 18;73(1):59-74
references.pmid: 11337060
references.citation: J Control Release. 2004 Mar 24;95(3):463-75
references.pmid: 15023458
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Biomaterials. 2010 May;31(14):3903-9
references.pmid: 20170957
references.citation: Biomaterials. 2008 Apr;29(10):1518-25
references.pmid: 18166223
references.citation: J Orthop Res. 2001 Nov;19(6):1098-104
references.pmid: 11781011
references.citation: J Pharm Sci. 1997 Dec;86(12):1464-77
references.pmid: 9423163